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Abstract
Background:  Human papillomavirus (HPV) is a crucial etiological factor for cervical  cancer (CC)
development. From a diagnostic view-point, the consistent presence  of HPV in CC allows the viral
DNA to be used as a genetic marker. The aims of  this study were to evaluate the presence, physical
status and clinical  significant of HPV DNA in circulation of CC patients.
Results:  Whereas 6 out of 50 (12%) HPV positive CC patients revealed plasma HPV DNA,  it was
detected in none of 20 normal controls or 13 HPV negative CC cases. The  plasma DNA exhibited
an HPV type identical to the HPV in the primary tumors and  the DNA from both sources was
integrated into host genome. Interestingly,  several findings suggested an association between
plasma HPV DNA and  metastasis. First, three of the HPV DNA positive cases were CC patients
with  clinical stage IVB or recurrence with distance metastases (P = 0.001, RR =  15.67). Second,
the amount of plasma HPV DNA from metastatic patients to be  three times more than three other
patients without metastases. Finally, the  later cases had tendency to develop recurrence distant
metastases within one  year after complete treatment when compared with other HPV associated
CC  patients with the same stage but without the present of plasma HPV DNA.
Conclusions:  The plasma HPV DNA originated from the CC, was associated with metastasis  and
could be used as a marker representing the circulating free CC DNA.
Background
Cervical cancer (CC) is one of the most common malig-
nancies in women  worldwide, especially in developing
countries [1].  Several studies have suggested that human
papillomavirus (HPV) initiates and  causes endogenous
genetic alterations in the progression of CC [2]. First, ep-
idemiological studies have shown that most human CCs
harbor  the "high risk" HPV types 16, 18, 31 and 33 [3,4].
Second, some HPV proteins such as E6 and E7 interact
with  human tumor suppresser gene products and
change cellular phenotypes [5]. Finally, the integration
linearizes HPV DNA between E1 and  L1 genes and dis-
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rupts the viral E2 gene, which consequently induces ex-
pression  of E6 and E7 genes [6,7]. This  genomic
rearrangement is thought to be critical for the transfor-
mation and  proliferation of the early precursors to these
cancers [1 ]. From a diagnostic viewpoint, the consistent
presence of HPV in CC allows the  viral DNA to be used
as a genetic marker. For example, cervical pre-malignant
lesions can be screened for highly sensitive HPV DNA
detection technology in  cell scrapings [8].
Accumulating lines of evidence have elucidated that
there is tumor DNA in  patients' circulation. Such DNA
can be detected in plasma or serum via specific  genetic
and epigenetic alterations of the primary tumor. Though
the mechanism  of this phenomenon is not clear, the
presence of tumor DNA in blood may have  diagnostic
and prognostic value [9,10,11,12]. Interestingly,  viral
DNA has been documented to occur as tumor DNA in the
circulation of  patients with primary tumors caused by vi-
ral infection. For example, there is a  high frequency of
hepatitis viral genomes and Epstein-Barr viral (EBV)
DNA in  the circulation of patients with hepatoma and
nasopharyngeal cancer (NPC),  respectively [13,14,15]. In
addition, the circulating EBV DNA may be an invaluable
tool for patient monitoring [15,16 ]. Since HPV DNA
serves as a genetic marker for CC, we tested whether
HPV DNA  could be detected in the plasma of CC patients
and whether it originated  directly from tumor cells.
Moreover, we determined whether the circulating HPV
DNA has any diagnostic and prognostic clinical potential
for patients with  CC.
Materials and methods
Sample Collection
Primary CC tissues were collected from 63 patients be-
fore treatment at King  Chulalongkorn Memorial Hospi-
tal. The tissues were divided into two parts. The  first part
was sent for routine histological examination. The sec-
ond part was  immediately stored in liquid nitrogen until
further use. All of the tumors were  histologically ascer-
tained to be CC and the staging was done according to
FIGO  criteria. The 63 tumors included stages ranging
from I to IV. All patients have  been followed for treat-
ment outcome and survival.
Blood samples were obtained by venipuncture from the
same patients and 20  healthy blood donors. To obtain
plasma, blood specimens in EDTA anticoagulant  were
centrifuged at 3,300 rpm for 10 min, and the plasma
were stored at  -20° C before use.
DNA Isolation
CC tissue was treated with SDS and proteinase K at 50° C
overnight,  followed by phenol/chloroform extraction
and ethanol precipitation of DNA.  Plasma DNA was pu-
rified on Qiagen columns (Qiamp blood kit; Qiagen, Ba-
sel,  Switzerland) according to the "blood and body fluid
protocol". Plasma (200  µ l) was processed using the col-
umn and one-tenth of the extracted DNA was  then used
for PCR analysis.
HPV Detection, Quantitation and Typing
For analysis of the HPV DNA in the plasma from CC pa-
tients, HPV E6 gene  amplification was performed using
a protocol previously described with some  modifications
[17]. The PCR reaction was in a total  volume of 20 µ l
containing 200 µ M of each dNTP, 10 µ M Tris-HCl  (pH
8.4), 50 mM potassium chloride, 4.0 mM magnesium
chloride, 0.5 units of  AmpliTaq Gold (Perkin Elmer Ce-
tus), 0.4 µ M of WD76 (CGGTTSAACCGAAAMCGG) and
WD67 (WGCAWATGGAWWGCYGTCTC), 0.1 µ M of
WD66 (AGCATGCGGTATACTGTCTC), WD 72 (CG-
GTCGGGACCGAAAACGG) and WD154 (TCCGTGT-
GGTGTGTCGTCCC). Additionally,  another PCR using
0.3 µ M of primers specific for ZP3, a gene on  the human
X chromosome, were performed to test the quality of
DNA [18]. For testing DNA and screening for HPV inci-
dence, one ZP3 primer, and WD72 and WD76, respec-
tively, were end labelled at 37° C for 1-2 h in a total
volume of 10 µ l containing 10 µ M primer, 0.025 mCi [γ -
32P] ATP (Amersham-Pharmacia) at 3000 Ci mmol-1,10
mM magnesium chloride, 5 mM DTT, 70 mM Tris-HCl
(pH 7.6) and 10 units of T4  polynucleotide kinase (New
England Biolabs). Without further separating of the  un-
incorporated nucleotides, the kinase reaction was added
to the PCR buffer  mix. The PCR amplifications were per-
formed as follows: initial denaturation at  95° C for 10
min, followed by 40 cycles of denaturation at 95° C for 1
min, annealing at 55° C for 1 min, extension at 72° C for 2
min and a  final extension at 72° C for 7 min. Reaction
products were mixed with  loading buffer and loaded
onto a 4% non-denaturing polyacrylamide gel. DNA
fragments were size fractionated at 800 V until the track-
ing dye had covered  the appropriate distance of the gel.
After electrophoresis, the wet gel was  transferred to fil-
ter paper (Whatman), wrapped with Saran wrap and ex-
posed to a  phosphorus screen; the bands were visualized
on PhosphoImager using ImageQuaNT  software (Mo-
lecular Dynamics). E6 and ZP3 primer pairs yielded 243
and 177 bp  PCR products, respectively. For HPV typing,
50 µ l of unlabeled PCR product  was prepared for dot
blot experiments. All HPV DNA positive plasma and
some  tumor DNA samples were measured semiquanti-
tatively by performing duplex  radiolabeled E6 and ZP3
primer PCR and repeating the above PCR reaction [18].
The difference between viral and host genome copy
numbers  was calculated from the relative intensity of
PCR bands by the imageQuaNT  software (Molecular Dy-
namics).BMC Cancer (2001) 1:2 http://www.biomedcentral.com/1471-2407/1/2
E6 type-specific probes were used for HPV typing. Posi-
tive controls of HPV  type 6, 11, 16, 18, 31 and 33 from
each PCR amplification were included [17]. Products ob-
tained from another unlabeled E6 PCR reaction  were
heated to 95° C and thereafter 1 volume of 20 X SSC was
added.  Aliquots of 40 µ l were applied to a Hybond-N+
nylon membrane  (Amersham Pharmacia Biotech) under
vacuum, prewetted in denaturing solution  (1.5 M NaCl,
0.5 M NaOH). The membranes were transferred to a fil-
ter paper  soaked in neutralizing solution (1.5 M NaCl,
0.5 M Tris-HCl pH 7.2, 0.001 M  EDTA) for 1 min. The
membranes were air dried at room temperature, soaked
in  0.4 M NaOH for 20 min for fixation and washed with
5 X SSC. Prehybridization at  65° C for 1 h was carried out
using 6 X SSC, 5 X Denhardt's solution, 0.5%  SDS and
100 µ g of single-stranded sheared salmon sperm DNA
per ml.  Replicate membranes were separately hybrid-
ized with denatured 32 P-labelled, type-specific probes in
prehybridizing solution for 1 hr at  55° C. Probes WD170
(GCAAGACATAGAAATAA) required hybridization at
45° C. Filters were rinsed briefly in 2 X SCC and 0.1% SDS
at room  temperature and then twice for 10 min at 45° C
(WD170), 50-52° C (WD132 (GACAGTATTGGAACTTA-
CAG), RR1 (GTACTGCACGACTATGT) and RR2 (AC-
CTTTGCAACGATCTG)), 55-56° C (WD103
(CAACAGTTACTGCGACG), WD165 (AAATCCTGCA-
GAAAGACCTC) and  WD166(CCTACAGACGCCATGT-
TCA)), or 56-57° C (WD133
(ACACCTAAAGGTCCTGTTTC) and WD134 (ACACTCT-
GCAAATTCAGTGC)). The membranes were exposed to a
Table 1: Plasma HPV DNA in tumor, Clinical staging, and treatment outcome of  50 HPV associated CC patients
Total Plasma HPV DNA
Positive Negative
Cervical Cancer patient 50 6 44
Agea
<50 25 3 22
>50 25 3 22
HPV type
Ub 40 4
16 28 2 26
18 16 4 12
33 2 0 2
Stage  
IB 2 0 2
IIB 17 3 14
IIIB 28 0 28
IVB 1 1 0
Rc 22 0
IIB response to radiotherapy
PRd 32 1
CRe 15 1 13
IIB clinical outcome within
one year after complete  
treatment  
Rc 62 4
NEDf 50 5
Metastases
Positive 3 3 P = 0001 0
Negative 47 3 RR = 15.67 44
Histopathology type
Squamous 42 5 37
Adenomatous 8 1 7
a<50 and >50 age less than 50, and above 50,  respectively; b U, unknown; c R, recurrence: d PR, partial response; e CR, complete response; f NED, 
no  evidence of diseaseBMC Cancer (2001) 1:2 http://www.biomedcentral.com/1471-2407/1/2
phosphorus screen and the signals were visualized on a
PhosphoImager using ImageQuaNT  software (Molecu-
lar Dynamics).
Detection of HPV Integration by PCR
All DNA samples from plasma and tissue that were posi-
tive for HPV type 16  and 18 were analyzed in two PCR re-
actions. One used 0.5 µ M of each primer  (5' E2
consensus primer HPV-16/18 5'-ATGAAAATGAYAG-
TAMAGAC-3', 3' E2 primer HPV-16 5'-CCAGTA-
GACACTGTAATAG-3' and HPV-18 5'-
CATTGTCATGTATCCCACC-3'), with 32P-labelled HPV-
16/18 to detect 1026 and 1028 bp PCR products from
HPV 16 and 18 episomal forms, respectively [7]. The oth-
er  used 0.5 µ M of each primer of PIGR gene (PIGR-F 5'-
TCAGCCAGGGTAAGGATCC-3' and PIGR-R 5'-TGAT-
GGTCACCGTTCTGCC-3') to  amplify a 1392 bp fragment
of human genomic DNA as a control. The PCR reactions
contained 200 µ M dNTP each, 10 µ M Tris-HCl (pH 8.4),
50 mM potassium  chloride, 1.5 mM magnesium chlo-
ride, 0.5 units of Thermus aquaticus  DNA polymerase
(Perkin Elmer Cetus), and the PCR amplifications were
performed  as follows: initial denaturation at 95° C for 5
min, followed by 40 cycles  of denaturation at 95° C for 1
min, annealing at 45° C for E2 gene or  55° C forPIGR for
1 min, extension at 72° C for 3 min and a  final extension
at 72° C for 7 min. Reaction product was mixed with load-
ing  dye and loaded onto 4% non-denaturing polyacryla-
mide gel. DNA fragments were  size fractionated at 800
V until the tracking dye had covered the appropriate  dis-
tance of the gel. After electrophoresis, the wet gel was
transferred to  filter paper (Whatman), wrapped with
Saran wrap and exposed to a phosphorus  screen. The
bands were visualized on a PhosphoImager using Image-
QuaNT software  (Molecular Dynamics).
Correlation between Clinical Data and Plasma HPV DNA
Data regarding histology, tumor staging, clinical pheno-
types, treatment  outcome, and HPV PCR and typing
were collected in a double-blind fashion until  analyzed.
The Fisher's exact test was used to compare the results
obtained from  plasma analysis with those of HPV and
clinical parameters.
Results
HPV DNA in Plasma
To determine whether HPV DNA could be detected in the
circulation of CC  patients and represented tumor DNA,
DNA from the plasma of three groups was  studied. The
first two comprised 63 positive and negative HPV CC pa-
tients, and  the other 20 healthy female blood donors.
The patients included in this study,  were classified by
age, pathological structure, and stage (Table  1). The con-
trol marker, ZP3, was positive in all samples. As a result,
all were further analyzed for the presence of HPV DNA
by PCR using labeled E6  degenerate primers. Plasma
HPV DNA was a specific genetic marker for HPV  associ-
ated CC, since it was detectable from neither HPV nega-
tive CC nor normal  controls. Nevertheless, the
circulating DNA had low sensitivity. Only 6 out of  50
(12%) with HPV associated CC patients were demon-
strated to have circulating  HPV DNA (Fig 1A and Table
1).
The frequency and type of HPV DNA were reevaluated
from all plasma and tumor  samples by PCR using the E6
degenerate primers and dot blot hybridization using
type specific oligonucleotides (Fig 1B and Table 1,2). The
presence of HPV DNA status was  confirmed and plasma
HPV DNA showed the same viral type as the tumors.
Furthermore, DNA from both plasma and tumor from
the 6 plasma-positive cases  were differentiated between
integrated and episomal. Since the integration  process
disrupts the HPV E2 gene, PCR using radioactive labeled
E2 primer would  show positive result from episomal
form of HPV but negative if the DNA  integrated (Fig 1C).
Whereas E2 PCR product was  detectable in 20.75% of
the HPV positive tumors, none of the plasma or tumor
samples from plasma HPV DNA positive CC patients was
positive (Fig 1D). In consideration with the absence of
episomal HPV DNA from  tumor, it is most likely that the
negative E2 PCR result was due to plasma HPV  DNA de-
rived from integrated HPV genome. This observation
suggested that the  circulating free HPV DNA originated
from the CC and thus could be used as a  marker for tu-
mor DNA.
Plasma HPV DNA and Clinical Correlation
To elucidate the importance and meaning of CC DNA
present in plasma, the  correlation between the presence
and amount of plasma HPV DNA and clinical data  was
investigated (Table 1). Clinical data including age,  stag-
ing, metastasis, response to treatment, and site of recur-
rence of plasma  HPV DNA positive patients were
included inTable 2.  Interestingly, there was an associa-
tion between plasma HPV DNA and metastasis.  Three
out of six plasma HPV DNA positive patients but none of
the other  patients with HPV associated cancers had dis-
tant metastasis at the time of  blood analysis (P < 0.001,
RR = 15.67 (5.24<RR<46.83)). One of the  three was
stage IVB and two had a recurrence distant metastasis,
one of whom  had previously been plasma HPV DNA
negative at stage IIIB. In addition, we  evaluated the
amount of HPV DNA in circulation by semi-quantitative
PCR,  comparing the intensity of PCR products between
HPV E6 gene and ZP3, a  gene on the human X chromo-
some. The average intensity ratio between these two
bands from tumor DNA and plasma DNA samples was
one and 0.08, respectively (Fig  1E and Table 2). Plasma
from one of  the patients, 106, was collected twice at dif-BMC Cancer (2001) 1:2 http://www.biomedcentral.com/1471-2407/1/2
Figure 1
HPV DNA in plasma of patients with cervical cancer. (A) PCR  generating 243-bp DNA fragments of HPV E6 gene (B)
Dot-blot  hybridization for HPV 18 probe Lanes a1-f1 were positive controls using  purified plasmids of HPV type 6, 11, 16, 18,
31 and 33, respectively Lanes  a2-f2 were plasma DNA from patients number 4, 106, 148, 161, 183, and 59  respectively Lanes
a3-f3 were tumor DNA from the same patients as lanes a2-f2  ( C) PCR generating 1392- and 1028-bp DNA fragments of
human PIGR  genomic sequence and HPV-18 E2 (D) PCR generating 1026,  1028-bp DNA fragments of HPV 16 and 18 E2 gene,
respectively, from tumor DNA on  a 2% agarose gel stained with ethidium bromide ( E) Duplex PCR generating  243- and 177-
bp DNA fragments of HPV E6 gene and human ZP3 genomic  sequence, respectively From left to right of A, C-E: M, 100-bp
ladder standard  DNA size marker; - and +, PCR products of the negative control  (double-distilled water) and positive control
(Hela cell line for A and E;  purified plasmids for D; and for C, DNA from human leukocyte for  PIGR  and purified HPV 18 DNA
plasmid for E2 gene), respectively; numbers without p  indicate PCR products of tumor DNA; numbers with p indicate PCR
products of  plasma DNA of CC patients Number 1061p and 1062p were plasma DNA from patient  106 but the samples
were collected at different timeBMC Cancer (2001) 1:2 http://www.biomedcentral.com/1471-2407/1/2
ferent time and demonstrated the  identical ratio (Fig
1E). Furthermore, the ratios from  the three plasma sam-
ples of patients with metastases, 0.05, 0.14, and 0.19,
was  higher, though not statistically significant, p =
0.098, than from the other  three non-metastasis pa-
tients, 0.02, 0.04, and 0.05. Interestingly, the three
plasma HPV DNA positive patients who were stage IIB
did not have as good a  clinical outcome when compared
with the other plasma HPV DNA negative patients  with
the same stage. Whereas 13 out of 14 plasma negative
cases had a complete  response to radiotherapy, 2 out of
the 3 circulating viral DNA positive cases  were partially
resistant. However, formal comparison did not yet show
significant statistical value, p = 0.063. In addition, we
found that plasma HPV  DNA positive patients may have
tendency to develop recurrent disease. In  patients who
was followed up for more than one year, 2 out of 2 and 4
out of 9  plasma HPV DNA positive and negative pa-
tients, respectively, suffered  reappearance of CC.
Discussion
The results of the present investigation confirm that it is
possible to  identify HPV DNA in DNA extracted from the
plasma of patients with CC. More  importantly, there are
at least three findings suggesting that the viral DNA
most likely originates from the tumor itself. First, circu-
lating HPV DNA was  not present in normal controls or
HPV negative CC. In addition, all HPV DNA  derived
from HPV-associated CC patients' circulation was type
16 or 18. These  high-risk HPV types are frequently asso-
ciated with high-grade cervical  intraepithelial neoplasia
and CC [4,19]. Second, the plasma DNA exhibited an
HPV type identical to the  primary tumors in the pa-
tients. Thus the possibility that HPV DNA in  circulation
is derived from another latent epithelial infection was re-
mote.  Finally, the HPV genomes from both tumor and
plasma were revealed the same  physical status by inte-
grating into the host genome. This was a unique  charac-
teristic for CC development and confirmed that the
circulating viral DNA  was from cancer cells [6,7].
Though both NPC and CC are viral associated lymphoep-
ithelioma, squamous  epithelial tumor with heavily lym-
phocyte infiltration, the incidence and  physical status of
viral DNA in the circulation and in tumors suggests that
the  DNA is released into the circulation of NPC and CC
patients via a different  mechanism. A much higher fre-
quency of circulating EBV DNA has been discovered  in
NPC [15,16]. In addition,  serum EBV DNA is resistant to
Dnase treatment [15]. In  conjunction with the expres-
sion and high antibody titer of lytic replication  genes in
NPC patients, it is likely that some circulating EBV DNA
in NPC is  virion associated [15,20,21]. In contrast to
EBV, at least two lines of evidences  indicated that plas-
ma HPV DNA was free DNA, not virion-associated. First,
the  clinical phenotype associated with circulating DNA
was similar between head and  neck squamous cell can-
cer (HNSCC) and CC. A recent study used human promo-
tor  hypermethylation as a serum marker and
demonstrated an association between this  epigenetic
marker and metastasis [22]. In addition,  circulating
HPV DNA could be found in a low percentage and asso-
ciate with  metastasis not only of CC cases but also of
HNSCC cases where the primary tumor  harbors HPV
DNA [23]. The other reason that argues  against the pos-
sibility that circulating HPV DNA is virion-associated is
that  the viral genome has integrated into the host ge-
nome with consequent deletion  of part of the HPV ge-
nome. This physical characteristic is unique to HPV
carcinogenesis and prevents viral ability to undergo
complete lytic  replication. All this evidence suggested
that the mechanism by which viral DNA  is released into
the circulation of NPC and CC, although both are viral
associated squamous epithelial cancers, is distinct.
Table 2: Clinical parameters and HPV characteristics of 6 plasma HPV DNA  positive CC patients
Patient Age Stagea Pathology Tumor Response to Time Metastatic HPV Relative
Code Type Size Radiotherapy Recur Organ type amount of
(cm) (month) b   E6:ZP3
 P C R  f
4 39 IIB Adenomatous 7 Partial 18 0.02
148 65 IIB Squamous 3 Complete 8 Pleura, 18 0.04
  Peritoneumc
183 27 IIB Squamous 6 Partial 11 Bone c 18 0.05
106 51 IVB Squamous >4 Liver, Pleurad 18 0.14
161 34 Re Squamous 7 Umbillicus d 16 0.19
59 46 Re Squamous 5 Liver, Lung d 16 0.05
a Stage at the time of blood examination; bTime  for recurrence after complete treatment; c Metastasis at time of  recurrence; d Metastasis at time 
of plasma DNA analysis; e R, recurrence; f Average amount from two experimentsBMC Cancer (2001) 1:2 http://www.biomedcentral.com/1471-2407/1/2
This study indicated that plasma HPV DNA was a specif-
ic, but not a  sensitive, genetic marker for CC diagnosis.
More importantly, there was a  strong association be-
tween plasma HPV DNA and metastasis, both when con-
sidering  incidence and amount of the circulating viral
DNA. Plasma HPV DNA positive  non-metastatic CC pa-
tients had tendency toward poor clinical outcome and
development of recurrent distant metastasis. This was
not surprising. Although  a variety of studies have shown
that patients with very early stage disease can  harbor
free circulating tumor DNA, several reports have re-
vealed plasma tumor  DNA to be more commonly detect-
able in advanced stage disease, to correlate  inversely
with clinical outcome and to correlate with a tendency to
fail with  effective treatment [9,22,23,24,25,26]. There
were at least three possible explanations for the  associa-
tion between plasma CC DNA and metastasis. The most
common hypothesis is  that circulating cancer DNA due
to the lysis of circulating cancer cells or  micrometastasis
shed by the tumor. HPV-specific mRNA has been found
in peripheral blood cells, circulating micrometastatic CC
cells, and lymph nodes of advanced-stage CC patients
with metastasis [27 ,28]. Nevertheless, a study of the rel-
ative amount of  DNA in the plasma of pancreatic cancer
patients indicated that a number of  circulating cancer
cells was insufficient and rejected this hypothesis [29].
Second, some in vitro and vivo studies have suggested
that circulating tumor DNA in plasma might play a role
in metastasis because of  its high transforming activity
[30, 31]. Finally, because there is a tendency toward poor
clinical outcome  for plasma HPV DNA positive CC pa-
tients, the mechanism to actively release  tumor DNA
into circulation might occur late during the multistep
process of CC  development when metastasis is more
likely [10].  Regardless of the mechanisms, our data show
that plasma HPV DNA in viral  associated CC should be
an independent genetic marker to predict disease  pro-
gression and clinical outcome.
Conclusions
The results of the present investigation indicated that it
was possible to  identify HPV DNA in DNA extracted
from the plasma of some patients with CC.  More impor-
tantly, The HPV genomes from both tumor and plasma
were revealed the  same type and physical status by inte-
grating into the host genome. Thus the  viral DNA most
likely originated from the tumor itself and the plasma
HPV DNA  represented the circulating free cell CC DNA.
Finally, plasma HPV DNA was a  specific, but not a sen-
sitive, genetic marker in which strongly associated with
CC metastasis.
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